Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Overview
Stock Information
Nasdaq:
COCPPrice
Change
Mkt Cap
Volume
52 week Low/High
Day Low/High
We are a clinical-stage biotechnology company developing novel therapeutics to meet the growing global need for effective, safe antiviral treatments. We employ a unique structure-based drug discovery technology platform and Nobel Prize-winning expertise to create first- and best-in-class antiviral drugs. Our antivirals target the replication process and are designed to be safe, broad-spectrum, resistant and convenient to administer.
We are quickly and efficiently advancing multiple programs with clinical development underway for influenza, norovirus and coronaviruses, while also discovering and developing antiviral compounds for other high-value indications.
Cocrystal Pharma to Extend Phase 2a Influenza Challenge Study with Oral PB2 inhibitor CC-42344
Co-Chief Executive Officer and President
Co-Chief Executive Officer and Chief Financial Officer
Chairman of the Board, Chief Scientist and Chairman of Scientific Advisory Board
Vice Chairman
Director
Director
Director
Director